G250E and Q252H are also present on the P-loop region but are not in direct contact to affect BIX-01294 ponatinib binding. The remaining three mutants in ABL kinase structure are located away from ponatinib binding site but are Sodium laureth sulfate inhibited by ponatinib. The binding free energies calculated from SIE indicated that these mutants may be involved in the long range interactions with ponatinib. The free energies and reaction field energies from Table 1 explain the important contributions from these mutant residues. The free energy binding changes of protein �C inhibitor complex with mutation provides an overall estimate of the increased or decreased affinity in complex formation. In this work, we observed that SIE free energy of binding does not vary appreciably in all complexes which are indicative that ponatinib is an effective inhibitor of native and all mutant BCR-ABL kinases which is in agreement with the experimental results. Therefore, in order to decipher the contributions from each residue in ponatinib binding region, we have deconvoluted the energy contributions for interactions between ponatinib and BCR-ABL kinase into electrostatic and vdW type. The electrostatic part represents columbic interactions that include chargecharge and other multipole interactions. The vdW part is van der Waals forces of attraction or contact energy term. These two terms represent major part of non-bonding interactions in MD simulations. In general terms, a positive value indicates a reduction in binding energy where as negative energy indicates that the binding is stronger. The values of energy contribution from individual amino acid residues in ponatinib binding pocket are shown in Table 2 and the active site amino acid residues with ponatinib are shown in Figure 1.Such high doses of PXD101 are more likely to repress p-AKT and p-ERK. Our study additionally demonstrates that multiple molecular events induced by PXD101 may cause cytotoxicity, and shows the efficacy of combination therapy using PXD101 with conventional chemotherapy currently in use for anaplastic thyroid cancer. Importantly, we demonstrate synergistic effects of combination PXD101 with doxorubicin and paclitaxel, suggesting likely clinical significance in treating patients with ATC. In conclusion, PXD101 imposed significan
